PACIRA BIOSCIENCES INC (PCRX) competitors & alternatives
Health Care · NASDAQ
PACIRA BIOSCIENCES INC (PCRX)'s top competitors and alternatives — its most similar public companies — include HERON THERAPEUTICS INC (HRTX), Stryker Corporation (SYK), AVANOS MEDICAL INC (AVNS), ANIKA THERAPEUTICS INC (ANIK), XOMA ROYALTY CORP (XOMA), CRISPR THERAPEUTICS AG (CRSP), VOYAGER THERAPEUTICS INC (VYGR), PTC THERAPEUTICS INC (PTCT), LINEAGE CELL THERAPEUTICS INC (LCTX), SANA BIOTECHNOLOGY INC (SANA), Sarepta Therapeutics (SRPT) and VOR BIOPHARMA INC (VOR). These are PACIRA BIOSCIENCES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top PCRX competitors & alternatives
-
HERON THERAPEUTICS INCHRTXHealth Care
A commercial-stage biotech company bringing specialized injectable medicines to acute care and oncology settings, with a focus on non-opioid pain management…
$0.47 (as of 2026-07-22) · market cap $90M
-
Stryker CorporationSYKHealth Care
A diversified medical technology leader offering surgical equipment, orthopedic robotics, and minimally invasive neurovascular products that collectively serve…
$309.24 (as of 2026-07-22) · market cap $119.6B
-
AVANOS MEDICAL INCAVNSHealth Care
Avanos Medical delivers non-opioid pain management and specialized nutrition feeding devices to hospitals and home care providers, reducing opioid dependency…
$24.98 (as of 2026-07-22) · market cap $1.2B
-
ANIKA THERAPEUTICS INCANIKHealth Care
Anika Therapeutics manufactures and markets hyaluronic acid (HA)-based medical products for orthopedic pain management, tissue regeneration, and non-orthopedic…
$15.01 (as of 2026-07-22) · market cap $199M
-
XOMA ROYALTY CORPXOMAHealth Care
A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights…
$40.17 (as of 2026-07-21) · market cap $710M
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
VOYAGER THERAPEUTICS INCVYGRHealth Care
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while…
$3.10 (as of 2026-07-22) · market cap $187M
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
LINEAGE CELL THERAPEUTICS INCLCTXHealth Care
Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships…
$1.11 (as of 2026-07-22) · market cap $278M
-
SANA BIOTECHNOLOGY INCSANAHealth Care
Sana Biotechnology is developing ex vivo and in vivo engineered cell therapy platforms to transform the treatment of diseases like type 1 diabetes, oncology,…
$3.12 (as of 2026-07-22) · market cap $868M
-
Sarepta TherapeuticsSRPTHealth Care
A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare…
$15.82 (as of 2026-07-22) · market cap $1.7B
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
Not quite? Describe exactly what you want →
Peers are PACIRA BIOSCIENCES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: PACIRA BIOSCIENCES INC (PCRX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.